10.15
5.84%
0.56
After Hours:
10.19
0.04
+0.39%
CorMedix Inc stock is traded at $10.15, with a volume of 1.50M.
It is up +5.84% in the last 24 hours and up +14.04% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$9.59
Open:
$9.58
24h Volume:
1.50M
Relative Volume:
1.35
Market Cap:
$615.87M
Revenue:
$65,400
Net Income/Loss:
$-46.34M
P/E Ratio:
-11.80
EPS:
-0.86
Net Cash Flow:
$-38.74M
1W Performance:
-21.74%
1M Performance:
+14.04%
6M Performance:
+73.80%
1Y Performance:
+190.83%
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-17-21 | Initiated | Needham | Buy |
Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
Sep-21-20 | Initiated | Truist | Buy |
Dec-18-19 | Initiated | B. Riley FBR | Buy |
Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
Dec-06-18 | Initiated | ROTH Capital | Buy |
Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
May-05-17 | Reiterated | Rodman & Renshaw | Buy |
Nov-11-16 | Reiterated | FBR & Co. | Outperform |
Mar-17-16 | Reiterated | FBR Capital | Outperform |
Mar-03-16 | Initiated | FBR Capital | Outperform |
Nov-16-15 | Reiterated | ROTH Capital | Neutral |
Oct-29-15 | Reiterated | ROTH Capital | Neutral |
May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
Dec-08-14 | Reiterated | ROTH Capital | Buy |
Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
CorMedix's SWOT analysis: defencath launch boosts stock outlook - Investing.com India
CorMedix's SWOT analysis: defencath launch boosts stock outlook By Investing.com - Investing.com UK
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium - The Manila Times
Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts - Simply Wall St
Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic - Yahoo Finance UK
While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate - Yahoo Finance UK
Recent 23% pullback isn't enough to hurt long-term CorMedix (NASDAQ:CRMD) shareholders, they're still up 188% over 1 year - Simply Wall St
CorMedix Inc. (NASDAQ:CRMD) Q3 2024 Earnings Call Transcript - Insider Monkey
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates - MSN
CorMedix Inc. Reports Q3 2024 Financial Results - TipRanks
CorMedix (CRMD) Q3 2024 Earnings Call Transcript - The Motley Fool
Earnings call: CorMedix Inc. reports Q3 financials, DefenCath drives growth - Investing.com
Earnings call: CorMedix Inc. reports Q3 financials, DefenCath drives growth By Investing.com - Investing.com UK
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
CorMedix: Q3 Earnings Snapshot - Press of Atlantic City
CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update - The Manila Times
CorMedix earnings beat by $0.06, revenue topped estimates - Investing.com UK
CorMedix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stellantis N.V. (STLA-N) QuotePress Release - The Globe and Mail
Cormedix Inc (CRMD) Q3 2024 Earnings Report Preview: What To Loo - GuruFocus.com
CorMedix stock soars to 52-week high, hits $13.52 - Investing.com India
CorMedix 2.0: New Leadership, New Approval, New Focus (NASDAQ:CRMD) - Seeking Alpha
CorMedix stock soars to 52-week high, hits $13.52 By Investing.com - Investing.com UK
(CRMD) Trading Advice - Stock Traders Daily
Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital + - Seeking Alpha
Spotify Technology S.A. (SPOT-N) QuotePress Release - The Globe and Mail
CorMedix Inc. Announces New Data at ASN Kidney Week 2024 - The Manila Times
Mauritian Rupee/U.S. Dollar (MURUSD) QuotePress Release - The Globe and Mail
CorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024 - The Manila Times
CorMedix Inc. (CRMD): A Bull Case Theory - Insider Monkey
Teucrium Wheat (WEAT-A) QuotePress Release - The Globe and Mail
CorMedix stock soars to 52-week high, hits $11.07 By Investing.com - Investing.com Australia
CorMedix stock soars to 52-week high, hits $11.07 - Investing.com
CorMedix Stock: Delayed Approval, Low Cash, Good Prospects (NASDAQ:CRMD) - Seeking Alpha
Objective long/short (CRMD) Report - Stock Traders Daily
Views of Wall Street’s Leading Experts on CorMedix Inc - SETE News
CRMD underperforms with a -0.59 decrease in share price - US Post News
CorMedix stock soars to 52-week high, hits $10.15 By Investing.com - Investing.com Australia
CorMedix stock soars to 52-week high, hits $10.15 - Investing.com India
Cormedix stock positioned for growth as DefenCath launch gains traction in 2H24 By Investing.com - Investing.com South Africa
CorMedix Inc (CRMD) receives a Buy rating from Rodman & Renshaw - Knox Daily
Stocks of CorMedix Inc (CRMD) are poised to climb above their peers - SETE News
CorMedix Inc Inc. (CRMD) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Cormedix stock positioned for growth as DefenCath launch gains traction in 2H24 - Investing.com Australia
Deeper Dive: Understanding CorMedix Inc (CRMD) Through its Various Ratios - The Dwinnex
CorMedix Stock Trends After New Commercial Agreement with Dialysis Operator: Retail Spirit Stays ‘Bullish’ - Barchart
CorMedix Inc (CRMD) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):